Sarepta Therapeutics, Inc. Research And Development Expense

Quick Answer

Sarepta Therapeutics, Inc. reported Research And Development Expense of $401.84 million for the year ending 2018.

  • Sarepta Therapeutics, Inc. showed an increase of +141.0% in Research And Development Expense from 2017 to 2018.
  • This data is from Sarepta Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 28, 2019.
  • XBRL data for this metric is available from 2009 to 2018 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Quarterly values from 10-Q filings: Q2 2010: $6.93 million | Q3 2010: $9.06 million | Q1 2011: $14.80 million | Q2 2011: $17.75 million | Q3 2011: $15.61 million | Q4 2011: $18.70 million | Q1 2012: $14.81 million | Q2 2012: $13.85 million | Q3 2012: $10.91 million | Q4 2012: $12.83 million | Q1 2013: $13.76 million | Q2 2013: $12.98 million | Q3 2013: $21.09 million | Q4 2013: $25.08 million | Q1 2014: $20.91 million | Q2 2014: $20.64 million | Q3 2014: $21.85 million | Q4 2014: $30.83 million | Q1 2015: $39.17 million | Q2 2015: $29.18 million | Q3 2015: $36.67 million | Q4 2015: $41.38 million | Q1 2016: $38.83 million | Q2 2016: $44.35 million | Q3 2016: $34.35 million | Q4 2016: $70.75 million | Q1 2017: $29.12 million | Q2 2017: $58.91 million | Q3 2017: $34.24 million | Q4 2017: $44.44 million | Q1 2018: $46.20 million | Q2 2018: $122.85 million | Q3 2018: $86.58 million | Q4 2018: $146.21 million | Q1 2019: $90.55 million | Q2 2019: $113.27 million.
  • Over the full 10 years of available data (2009 to 2018), Sarepta Therapeutics, Inc.'s Research And Development Expense has grown by 1,547.2%.
  • Historical annual values: Fiscal year 2018: $401.84 million | Fiscal year 2017: $166.71 million | Fiscal year 2016: $188.27 million | Fiscal year 2015: $146.39 million | Fiscal year 2014: $94.23 million | Fiscal year 2013: $72.91 million | Fiscal year 2012: $52.40 million | Fiscal year 2011: $66.86 million | Fiscal year 2010: $35.97 million | Fiscal year 2009: $24.40 million.
  • Data sourced from SEC EDGAR public filings as of August 5, 2026.

Last verified: